Clinical Scenario

This protocol addresses metastatic gastrointestinal stromal tumor (GIST) in patients whose tumors carry a KIT exon 9 mutation — a molecularly defined subset that requires specific dosing considerations distinct from other GIST genotypes.

Molecular Context

KIT exon 9 mutation status is a key factor in determining the appropriate therapeutic approach for metastatic GIST. Evidence supports adjusted dosing for this molecular subset at the first treatment stage, making genotyping an essential step before initiating systemic therapy.

Treatment Approach

Management of this molecularly defined subset involves a targeted therapeutic agent, sunitinib, with specific scheduling options. The choice between available regimens and the criteria guiding that selection are detailed in the full protocol.

Complete regimen details — including schedule, dosing options, and sequencing criteria — are available in the structured protocol below.

References

DOI: 10.1177/17588359231192388

Imatinib 400 mg every 12 h is the recommended dose for GIST with KIT exon 9 mutation (II,A).
After the failure of imatinib, the standard second-line treatment is sunitinib 50 mg daily 4/2 (I,A) or 37.5 mg continuously (III,C).
The recommended dose is 50 mg orally once daily over 4 weeks followed by a 2-week rest period.
Specific molecular backgrounds benefit particularly from sunitinib treatment: KIT exon 9 primary mutation, SDH-deficient GIST, and secondary mutations in KIT exons 13 and 14.

View source ↗

Treatment of Metastatic Gastrointestinal Stromal Tumor with KIT Exon 9 Mutation

Clinical Scenario

Molecular Context

Treatment Approach

References